United States — Inside FDA OPDP— 21 CFR 202, Fair Balance, Warning Letters, and the Off-Label case law — the contour of the American oversight model

01Why International Comparison Strengthens Japanese Material Review

Japanese material reviewers can easily get sealed inside "the Japan-specific rules." The Pharmaceutical Act §66, the Advertising Appropriateness Standards, the Sales Information Provision Activity Guideline (HanteiG), the JPMA Code, internal SOPs — the five-layer net (Vol. 2) you stare at every day. But the lineage of these norms — where they came from, why they look like this — only becomes three-dimensional when read against overseas systems.

For instance, HanteiG's prohibition of "expressions that induce misperception, regardless of active or passive delivery" sits in close parallel to OPDP (the FDA office that reviews prescription drug advertising and promotion) and its "Truthful and Not Misleading" doctrine (= be truthful, and do not leave people with a false impression). Meanwhile, the U.S. concept of Fair Balance (= show the benefit claims and the side-effect information with "equal weight") is distinctive, and the Japanese notion of "fair balance" carries a direct translational legacy from it. Seeing the relationship, you can read Japan's regulation as a combination of historical inheritance and local evolution.

This sub-series (The International Lens, 3 episodes) walks through the U.S. → Europe → Asia structures in order. This piece is the U.S. installment. The goal is to make you able to articulate, in international context, why Japan reaches the judgments it does.

02The U.S. Regulatory Architecture — Four Layers

U.S. pharmaceutical advertising regulation rests on the following four layers. Read in parallel with Japan's five-layer net, the differences come into focus.

Notably, Japan's public regulatory architecture has four formal layers (law, public notices, guidelines, industry code) — colloquially called the "five-layer net" once each company's internal SOPs are added. The U.S. system has four layers. At first glance the U.S. system looks simpler, but in practice case law functions as a de facto fifth layer — Caronia and the rulings discussed below move the actual reach of regulation.
※ Internal SOPs are an internal implementation that companies in every country (U.S., Europe, Asia) maintain. For international comparison, the analytically correct approach is to compare public norms only; the tables below follow that convention.

0321 CFR 202 — The Reach of the Core Regulation

The center of U.S. prescription drug advertising regulation is the federal regulation 21 CFR 202.1 (= Title 21 of the Code of Federal Regulations, section 202.1 — the provision that sets the rules for prescription drug advertising). The text is long; the operative points are these.

Much of this text reads directly in parallel with Japan's Pharmaceutical Act §66 (prohibition of exaggerated advertising). The U.S. style is distinctive in directly prescribing the structure expression must take, rather than listing prohibited acts. Japan's §66 writes "exaggerated advertising is prohibited"; 21 CFR 202.1 writes "you must express things with Fair Balance." Structural prescription rather than prohibition.

04The Fair Balance Doctrine — the Core of the American Idea of Parity

Fair Balance is the most important concept for understanding U.S. advertising regulation. The essence:

"The advertisement must present a fair balance between information relating to side effects and contraindications and information relating to effectiveness of the drug." (21 CFR 202.1(e)(5)(ii))
— Information about efficacy and information about side effects / contraindications must be treated with fair parity.

This parity is not a mere "include the safety information" volume requirement. The FDA evaluates four dimensions:

• Visual Balance — Are the efficacy presentation and the safety presentation treated equivalently in font size, color, and placement? Efficacy in bold large type with side effects in a small footnote = violation.
• Temporal Balance — In TV / video ads, is the airtime spent on efficacy roughly balanced with the airtime spent on adverse events?
• Linguistic Balance — Efficacy stated in strong assertive language, with side effects in hedged or vague phrasing, is not acceptable.
• Contextual Balance — In the situation where the patient actually encounters the information, can they pay equivalent attention to both?

Japan's "fair balance" concept carries the translational legacy of this American doctrine. When HanteiG or the Advertising Appropriateness Standards demand "balance between efficacy and safety," the historical current of 21 CFR 202.1(e)(5)(ii) Fair Balance is flowing underneath.

05Substantial Evidence and Truthful Not Misleading

Alongside Fair Balance stand Substantial Evidence and Truthful and Not Misleading as the other foundational pillars.

Substantial Evidence

From the 1962 Kefauver-Harris Amendment onward, the indications FDA approves must rest on "adequate and well-controlled clinical investigations". The claims made in advertising cannot exceed the boundary of that approval. Promotion of off-label indications is, in principle, a §502 violation.

This concept parallels Material Review Vol. 3 (Efficacy Claims Within the Approved Scope). In Japan, Pharmaceutical Act §68 (pre-approval advertising) and the Advertising Appropriateness Standards carry the load; in the U.S., the load is carried by FDCA §502 + 21 CFR 202 + the case law discussed below.

Truthful and Not Misleading

The foundational principle set out in 21 CFR 202.1(e)(6). FDA judges advertisements under this standard. The reach of "Not Misleading" is broad — covering cases where "no explicit falsehood is present, but context or expression creates a false impression." This is the same conceptual shape as HanteiG §3(2)(i)'s prohibition of "expressions that induce misperception."

06OPDP Enforcement Tools — Warning Letter vs. Untitled Letter

When OPDP confirms a violation, it issues one of two graduated warning letters. The lighter one is the Untitled Letter (= a notice of concern with no formal heading); the heavier one is the Warning Letter (= a formal warning). Unlike Japan's PMDA practice, the U.S. system publishes the company name, the nature of the violation, and the specific cited material. Public exposure is the defining feature of American enforcement.

Recent representative OPDP Warning Letter examples:

• April 2020 — AcelRx Pharmaceuticals (DSUVIA) — Warning Letter for efficacy exaggeration and inappropriate omission of safety information. Risk information was treated in a manner lacking Fair Balance.
• January 2019 — Outlook Therapeutics (ANDEXXA) — Untitled Letter for "superior efficacy" claims judged to lack Substantial Evidence.
• September 2017 — Cipher Pharmaceuticals (Lipofen) — Untitled Letter regarding inappropriate placement of adverse-event warnings in promotional material.

07Off-Label Promotion Case Law — Caronia and Vascular Solutions

No description of U.S. regulation is complete without the case law on Off-Label Promotion in federal appellate courts. These rulings have irreversibly altered the practical reach of FDA's authority.

United States v. Caronia (2012, U.S. Court of Appeals for the Second Circuit)

In 2008, Alfred Caronia, a sales representative for Orphan Medical (= a medical sales rep, the role that conveys drug information to physicians), was indicted under FDCA §301(a) for discussing the off-label indications of the sodium oxybate product Xyrem with physicians. Convicted at jury trial, he was acquitted on appeal. The Second Circuit held that "the provision of truthful and not-misleading off-label information is protected speech under the First Amendment."

The ruling's reach is limited (Second Circuit only), but it cast a chilling effect on subsequent FDA enforcement. The FDA grew reluctant to bring criminal cases for off-label promotion alone, shifting toward strict enforcement at the boundary of "not misleading".

Amarin v. FDA (2015) and Vascular Solutions v. FDA (2016)

The logic of Caronia was extended in Amarin (high-purity EPA off-label promotion) and Vascular Solutions (varicose-vein device off-label promotion). In both cases, the companies argued "our off-label information is truthful and not misleading," and they effectively prevailed against FDA. The FDA materially lost both cases, and revised its Off-Label guidance substantially in 2018.

08DTC Advertising — A U.S.-Specific System

The most distinctive feature of U.S. pharmaceutical advertising is Direct-to-Consumer (DTC) advertising for prescription drugs. Unlike Japan, prescription drug TV ads, newspaper ads, and web ads can be aimed directly at consumers. After FDA's 1997 reinterpretation of "Adequate Provision," Brief Summary in TV format became practically feasible, and the DTC market expanded rapidly.

DTC advertising has its own taxonomy:

• "Reminder Ads" — show only the drug's name and packaging, with no indication mentioned. Brief Summary not required. The "if interested, ask your doctor" form.
• "Help-Seeking Ads" — describe the disease's symptoms or need for treatment without naming a product. In practice they are awareness campaigns for a specific drug, but regulatory scrutiny is lighter.
• "Product Claim Ads" — the standard form, asserting efficacy. Brief Summary and major side effects required. In TV ads, "Adequate Provision" (alternate-channel disclosure of risk information) is required.

In Japan, prescription drug DTC advertising is prohibited in principle (Pharmaceutical Act §66, §67). DTC applies only to OTC. So Japanese material reviewers have almost no practical experience with DTC rules. Going forward, however, cross-border digital ads — U.S.-built DTC content reaching Japanese patients — will become an issue worth tracking.

09PhRMA Code — The Role of Industry Self-Regulation

The fourth layer, the PhRMA Code on Interactions with Healthcare Professionals, parallels Japan's JPMA Code. Main contents:

• Limits on gifts to healthcare professionals (cash and cash equivalents prohibited; restricted to items of educational value)
• Limits on meals and hospitality (modest meals, only in connection with substantive meetings)
• Management of samples (restricted to patient-care purposes)
• Reasonableness of consulting agreements (fair market value compensation)
• Transparency around speaker and educational activities

What distinguishes the U.S. is that, on top of PhRMA Code compliance, the federal Anti-Kickback Statute (42 USC §1320a-7b) (= a law that forbids exchanging money or gifts for referrals where public health insurance is involved) and the Sunshine Act (Physician Payments Sunshine Act, 2010) (= a law that forces drug companies to disclose payments to physicians; "Sunshine" means bringing things into the open so they can be seen) impose legal obligations. Under the Sunshine Act, every payment from a pharmaceutical company to a healthcare professional above $10 is publicly disclosed (the CMS Open Payments database). This is the central mechanism of U.S. transparency.

10Compared with Japan — Five Structural Contrasts

The discussion to this point can be organized into five contrasts against Japan's "five-layer net."

These five contrasts are not about which system is superior. They are about different institutional choices in pursuit of the same goal. The U.S. design strongly protects expression (First Amendment) while using public enforcement to elicit industry self-discipline. Japan's design strongly foregrounds protection of patients and healthcare professionals, framing the industry's "trust as a good" as a collective responsibility. There is also institutional complementarity between them.

11Connections to Other Chapters on This Site

The U.S. comparison connects to other chapters of this site as follows.

• Yakugai History 01 — Why the birth of the FDCA (1938) became the starting point of American-style regulation.
• Yakugai History 02 — The path by which the U.S. alone was spared from thalidomide (Frances Kelsey's stand), and the 1962 Kefauver-Harris Amendment (efficacy plus oversight).
• Ad Regulations 01 — Reading the origins of Japan's Pharmaceutical Act §§66–68 alongside the American system.
• Material Review Vol. 2 — Japan's five-layer net compared with the U.S. four-layer-plus-case-law architecture.
• Material Review Vol. 3 — The correspondence between efficacy claims and Substantial Evidence.